Company Reports / Bayer Healthcare

COMPANY: Bayer Healthcare

INDEX RANK: 11th

Total Impact Score: 134,837.29

Bayer Healthcare is ranked 11th place in our index for 2015. Bayer Healthcare’s drugs have a total impact score of 134,837.29. Bayer Healthcare treats three diseases in our model - schistosomiasis, P. vivax malaria, and XDR-TB - with three total drugs - Praziquantel (PZQ), Chloroquine (CQ), and Moxifloxacin (Mfx). Bayer Healthcare receives credit for one treatment against schistosomiasis - Praziquantel (PZQ). This one drug averted 114,408.21 of the total DALYS for schistosomiasis, which is 100.00% of the worldwide DALYs that we estimate would have been lost due to schistosomiasis in 2015 in the absence of effective treatment. Bayer Healthcare’s drug portfolio placed it 1st in terms of total averted DALYs for schistosomiasis. Bayer Healthcare receives credit for one treatment against P. vivax malaria - Chloroquine (CQ). This one drug averted 13,781.63 of the total DALYS for P. vivax malaria, which is 3.53% of the worldwide DALYs that we estimate would have been lost due to P. vivax malaria in 2015 in the absence of effective treatment. Bayer Healthcare’s drug portfolio placed it 2nd in terms of total averted DALYs for P. vivax malaria. Bayer Healthcare receives credit for one treatment against XDR-TB - Moxifloxacin (Mfx). This one drug averted 6,647.45 of the total DALYS for XDR-TB, which is 9.38% of the worldwide DALYs that we estimate would have been lost due to XDR-TB in 2015 in the absence of effective treatment. Bayer Healthcare’s drug portfolio placed it in a tie for 5th in terms of total averted DALYs for XDR-TB.

Company Score Breakdown:

Key Drugs

CHLOROQUINE

Chloroquine (CQ) is an aminoquinoline recommended by the WHO as an alternative to ACTs in the treatment of uncomplicated malaria in areas with chloroquine-susceptible infections. Due to its good safety profile and well-documented effectiveness, it is a primary treatment of uncomplicated malaria, although resistance to chloroquine is widespread. It was first developed in 1934 by Hans Andersag, a researcher at Bayer.

MOXIFLOXACIN

Moxifloxacin (Mfx): A fluoroquinolone antibiotic, is a Group A second line drug used in the treatment of rifampicin-resistant and multidrug-resistant tuberculosis. It has a good safety profile and is relatively highly effective against TB. Side effects include seizure and gastrointestinal upset. The drug was patented by Bayer in 1997.

PRAZIQUANTEL

Praziquantel (Pzq) is an anthelmintic used to specifically treat schistosomiasis, liver flukes, and cysticercosis. it works by increasing the intra-tugument influx of Calcium which leads to rapid contractions of the worm and eventually death. Common side effects include abdominal discomfort, vertigo, and muscle aches. Praziquantel is on the WHO list of essential medicines. It is sold under the brand name Biltricide. Praziquantel was discovered by Bayer, though the patent has expired.

Company Information

The Bayer Group is a global pharmaceutical company founded in Germany in 1863 by Friedrich Bayer and Johann Friedrich Weskott. Bayer Healthcare strives towards innovation, health, and sustainability in multiple fields, including cardiology, gynecology, oncology, ophthalmology and hematology. They are currently working on the development of a new insecticide active ingredient to improve malaria control, investigating an active substance that may be effective in patients with river blindness, engaging in a clinical study to better dose children with Chagas’ disease, as well as awaiting the WHO evaluation of Fluodora® Fusion, a product that can be used to combat insecticide resistant mosquitoes. For ten years, Bayer has been supplying WHO, free of charge, with two substances against Chagas’ and African sleeping sickness. Notable products include Aspirin®, Aleve®, Avelox®, and LifeNet®, an insecticide infused anti- malarial net. Bayer has nearly 100,000 employees and had a net income of approximately $40 billion in 2017. Their group comprises 237 companies in 79 countries.

Company Report PDF

CONTACT US © 2017 GLOBAL HEALTH IMPACT